# Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

> **NCT03393884** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Imunon** · enrollment: 130 (estimated)

## Conditions studied

- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **BIOLOGICAL:** IMNN-001
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03393884
- **Lead sponsor:** Imunon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-09-05
- **Primary completion:** 2024-07-25
- **Final completion:** 2026-05-30
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03393884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03393884, "Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03393884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*